Description
The global market for Cystic Fibrosis Therapeutics is projected to reach $30.48 billion by 2030, driven by improving diagnosis rate, increased research activity, strong drug development pipeline and expected launch of novel treatments designed to address the high unmet patient needs.
The research report provides a comprehensive review of market trends, market growth drivers, PEST Analysis, Market growth inhibitors, and strategic industry activities and SWOT Analysis of key players in the market.
The report provides market estimates and forecast for geographic markets such as the North America (US, Canada, Mexico and Rest of North America), South America (Brazil, Argentina and Rest of South America), Europe (Germany, France, U.K., Russia, Italy, Spain, Sweden, Netherlands, Poland, Austria, Norway, Switzerland, Denmark and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Taiwan, India, Australia and Rest of Asia-Pacific), Middle East (Iran, Turkey, Kuwait, UAE, Israel and Rest of Middle East) & Africa.
Key players profiled in the report include AbbVie Inc., Galapagos NV, Genentech, Gilead Sciences Inc., Novartis AG, and Vertex Pharmaceuticals Incorporated., among others.
